Publications

1. Becirovic, E. (2022) Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications. Cell Mol Life Sci 79, 130

2. Riedmayr, L. M., Hinrichsmeyer, K. S., Karguth, N., Bohm, S., Splith, V., Michalakis, S., and Becirovic, E. (2022) dCas9-VPR-mediated transcriptional activation of functionally equivalent genes for gene therapy. Nat Protoc

3. Panagiotopoulos, A. L., Karguth, N., Pavlou, M., Bohm, S., Gasparoni, G., Walter, J., Graf, A., Blum, H., Biel, M., Riedmayr, L. M., and Becirovic, E. (2020) Antisense Oligonucleotide- and CRISPR-Cas9-Mediated Rescue of mRNA Splicing for a Deep Intronic CLRN1 Mutation. Mol Ther Nucleic Acids 21, 1050-1061

4. Bohm, S., Splith, V., Riedmayr, L. M., Rotzer, R. D., Gasparoni, G., Nordstrom, K. J. V., Wagner, J. E., Hinrichsmeyer, K. S., Walter, J., Wahl-Schott, C., Fenske, S., Biel, M., Michalakis, S., and Becirovic, E. (2020) A gene therapy for inherited blindness using dCas9-VPR-mediated transcriptional activation. Sci Adv 6, eaba5614

5. Riedmayr, L. M., Bohm, S., Biel, M., and Becirovic, E. (2020) Enigmatic rhodopsin mutation creates an exceptionally strong splice acceptor site. Hum Mol Genet 29, 295-304